Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Hagemann, Sabine ^a   Heil, Oliver ^a   Lyko, Frank ^a   Brueckner, Bodo ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DINUCLEOTIDE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3B; POLYCOMB REPRESSIVE COMPLEX 2; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; DNA (CYTOSINE 5 ) METHYLTRANSFERASE 1; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; DRUG DERIVATIVE; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER CELL CULTURE; COLON CANCER; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; DNA REPLICATION; DNA SEQUENCE; EMBRYONIC STEM CELL; GENETIC RESISTANCE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MYELOID LEUKEMIA; PROMOTER REGION; REGULATORY MECHANISM; REPRODUCIBILITY; CELL STRAIN HCT116; CELL STRAIN HL 60; CHROMATIN; CPG ISLAND; DNA MICROARRAY; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENETICS; HUMAN GENOME; METABOLISM; PROTEIN BINDING; TUMOR GENE;

AZACITIDINE; CHROMATIN; CPG ISLANDS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKOUT TECHNIQUES; GENES, NEOPLASM; GENOME, HUMAN; HCT116 CELLS; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN BINDING; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 79952328162     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017388     Document Type: Article

References (46)

1. Jones PA, Baylin SB, (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428.
2. Robertson KD, (2005) DNA methylation and human disease. Nat Rev Genet 6: 597-610.
3. Jones PA, Baylin SB, (2007) The epigenomics of cancer. Cell 128: 683-692.
4. Sakai T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM, et al. (1991) Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am J Hum Genet 48: 880-888.
5. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, et al. (1994) Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 91: 9700-9704.
6. Esteller M, (2007) Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8: 286-298.
7. Mund C, Hackanson B, Stresemann C, Lubbert M, Lyko F, (2005) Characterization of DNA demethylation effects induced by 5-Aza-2′-deoxycytidine in patients with myelodysplastic syndrome. Cancer Res 65: 7086-7090.
8. Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, et al. (2006) Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 66: 6361-6369.
9. Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, et al. (2007) Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110: 2302-2308.
10. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Kohler G, et al. (2002) Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 100: 2957-2964.
11. Stresemann C, Bokelmann I, Mahlknecht U, Lyko F, (2008) Azacytidine causes complex DNA methylation responses in myeloid leukemia. Mol Cancer Ther.
12. Taylor SM, Jones PA, (1982) Mechanism of action of eukaryotic DNA methyltransferase. Use of 5-azacytosine-containing DNA. J Mol Biol 162: 679-692.
13. Santi DV, Norment A, Garrett CE, (1984) Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci U S A 81: 6993-6997.
14. Schermelleh L, Spada F, Easwaran HP, Zolghadr K, Margot JB, et al. (2005) Trapped in action: direct visualization of DNA methyltransferase activity in living cells. Nat Methods 2: 751-756.
15. Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, et al. (2006) DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res 66: 5495-5503.
16. Gius D, Cui H, Bradbury CM, Cook J, Smart DK, et al. (2004) Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell 6: 361-371.
17. Schuebel KE, Chen W, Cope L, Glockner SC, Suzuki H, et al. (2007) Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet 3: 1709-1723.
18. Stresemann C, Lyko F, (2008) Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 123: 8-13.
19. Bibikova M, Le J, Barnes B, Saedinia-Melnyk S, Zhou L, et al. (2009) Genome-wide DNA methylation profiling using Infinium® assay. Epigenomics 1: 177-200.
20. Egger G, Jeong S, Escobar SG, Cortez CC, Li TW, et al. (2006) Identification of DNMT1 (DNA methyltransferase 1) hypomorphs in somatic knockouts suggests an essential role for DNMT1 in cell survival. Proc Natl Acad Sci U S A 103: 14080-14085.
21. Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, et al. (2002) DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416: 552-556.
22. Stach D, Schmitz OJ, Stilgenbauer S, Benner A, Dohner H, et al. (2003) Capillary electrophoretic analysis of genomic DNA methylation levels. Nucleic Acids Res 31: E2.
23. Grönniger E, Weber B, Heil O, Peters N, Stab F, et al. (2010) Aging and chronic sun exposure cause distinct epigenetic changes in human skin. PLoS Genet 6: e1000971.
24. Team RDC (2010) R: A language and environment for statistical computing. R Foundation for Statistical Computing Vienna, Austria.
25. Smyth GK, (2005) Limma: linear models for microarray data. In: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W, editors. Bioinformatics and Computational Biology Solutions using R and Bioconductor New York Springer pp. 397-420 p.
26. Sarkar D, (2008) Lattice: Multivariate Data Visualization with R. New York Springer.
27. Schaefer M, Pollex T, Hanna K, Lyko F, (2009) RNA cytosine methylation analysis by bisulfite sequencing. Nucleic Acids Res 37: e12.
28. Taylor KH, Kramer RS, Davis JW, Guo J, Duff DJ, et al. (2007) Ultradeep bisulfite sequencing analysis of DNA methylation patterns in multiple gene promoters by 454 sequencing. Cancer Res 67: 8511-8518.
29. Zambelli F, Pesole G, Pavesi G, (2009) Pscan: finding over-represented transcription factor binding site motifs in sequences from co-regulated or co-expressed genes. Nucleic Acids Res 37: W247-252.
30. Bryne JC, Valen E, Tang MH, Marstrand T, Winther O, et al. (2008) JASPAR, the open access database of transcription factor-binding profiles: new content and tools in the 2008 update. Nucleic Acids Res 36: D102-106.
31. Bender CM, Pao MM, Jones PA, (1998) Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res 58: 95-101.
32. Momparler RL, Samson J, Momparler LF, Rivard GE, (1984) Cell cycle effects and cellular pharmacology of 5-aza-2′-deoxycytidine. Cancer Chemother Pharmacol 13: 191-194.
33. Mossman D, Kim KT, Scott RJ, (2010) Demethylation by 5-aza-2′-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists. BMC Cancer 10: 366.
34. Weisenberger DJ, Campan M, Long TI, Kim M, Woods C, et al. (2005) Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res 33: 6823-6836.
35. Eckhardt F, Lewin J, Cortese R, Rakyan VK, Attwood J, et al. (2006) DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet 38: 1378-1385.
36. Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, et al. (2007) Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 39: 457-466.
37. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, et al. (2007) Epigenetic stem cell signature in cancer. Nat Genet 39: 157-158.
38. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, et al. (2007) Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 39: 232-236.
39. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, et al. (2006) Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 125: 301-313.
40. Yamashita K, Upadhyay S, Osada M, Hoque MO, Xiao Y, et al. (2002) Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2: 485-495.
41. Hollenbach PW, Nguyen AN, Brady H, Williams M, Ning Y, et al. (2010) A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 5: 1-10.
42. Qin T, Jelinek J, Si J, Shu J, Issa JP, (2009) Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines. Blood 113: 659-667.
43. Zaret KS, (2002) Regulatory phases of early liver development: paradigms of organogenesis. Nat Rev Genet 3: 499-512.
44. Xu J, Watts JA, Pope SD, Gadue P, Kamps M, et al. (2009) Transcriptional competence and the active marking of tissue-specific enhancers by defined transcription factors in embryonic and induced pluripotent stem cells. Genes Dev 23: 2824-2838.
45. Gebhard C, Benner C, Ehrich M, Schwarzfischer L, Schilling E, et al. (2010) General transcription factor binding at CpG islands in normal cells correlates with resistance to de novo DNA methylation in cancer cells. Cancer Res 70: 1398-1407.
46. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, et al. (1998) Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 19: 187-191.